Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes

被引：0
|
作者：
Ghorab, Ahmad [1 ]
Litzow, Mark [2 ]
Gangat, Naseema [2 ]
Al-Kali, Aref [2 ]
Shah, Mithun [2 ]
Murthy, Hemant [1 ]
Alkhateeb, Hasan [2 ]
Begna, Kebede [2 ]
Patnaik, Mrinal [2 ]
Foran, James [1 ]
Badar, Talha [1 ]
机构：
[1] Mayo Clin, Jacksonville, FL USA
[2] Mayo Clin, Rochester, MN USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
Relapsed/Refractory AML; FLT3; mutation; Hypomethylating Agents; Venetoclax; Clinical Outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-497
引用
收藏
页码：S306 / S306
页数：1
相关论文
共 50 条
  • [41] Combination of Venetoclax and Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: Single-Center Clinical Experience
    Secilmis, Sema
    Bozan, Ersin
    Darcin, Tahir
    Yaman, Samet
    Yigenoglu, Tugcenur
    Ulu, Bahar Uncu
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Yildiz, Jale
    Baysal, Nuran Ahu
    Iskender, Dicle
    Cakar, Merih Kizil
    Sinan, Dal Mehmet
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S192 - S193
  • [42] Venetoclax in Combination with Hypomethylating Agents Compared to Standard Chemotherapy in Relapsed/ Refractory Acute Myeloid Leukemia
    Mohassel, Leila
    Yakubi, Hanna
    Jones, Kendra
    Wang, Hongkun
    Shafer, Danielle
    BLOOD, 2022, 140 : 6158 - 6159
  • [43] Gilteritinib plus azacitidine and venetoclax for FLT3-ITD mutated relapsed/refractory acute myeloid leukemia
    Chen, Nianci
    Zhou, Yile
    Tong, Hongyan
    Wei, Juying
    Lou, YinJun
    Zhou, De
    Fan, Cuihua
    Huang, Li
    Mao, Liping
    Li, Chenying
    Wang, Huafeng
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
    Graveno, Molly E.
    Carulli, Alison
    Freyer, Craig W.
    Mangan, Brendan L.
    Nietupski, Robert
    Loren, Alison W.
    Frey, Noelle, V
    Porter, David L.
    Gill, Saar, I
    Hexner, Elizabeth O.
    Luger, Selina M.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Perl, Alexander E.
    Babushok, Daria, V
    Pratz, Keith W.
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1645 - 1650
  • [45] Quizartinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: More Patients Make It to Transplant, but Are There Any Other Benefits?
    Hunter, Bradley D.
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (02): : 99 - 100
  • [46] BURDEN OF ILLNESS OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) IN THE UNITED STATES
    Sotak, M.
    Marin, M.
    Coombs, J.
    Schiller, G.
    Teitelbaum, A.
    HAEMATOLOGICA, 2012, 97 : 35 - 35
  • [47] Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)Transplant Outcomes Post HMA Therapy in a Large International Patient Cohort
    Stahl, Maximilian
    Deveaux, Michelle
    Montesinos, Pau
    Itzykson, Raphael
    Ritchie, Ellen K.
    Sekeres, Mikkael A.
    Majhail, Navneet S.
    Podoltsev, Nikolai A.
    Fathi, Amir T.
    Komrokji, Rami S.
    Bhatt, Vijaya R.
    Al-Kali, Aref
    Cluzeau, Thomas
    Santini, Valeria
    Brunner, Andrew M.
    Roboz, Gail J.
    Fenaux, Pierre
    Litzow, Mark R.
    Perreault, Sera
    Kim, Tae Kon
    Prebet, Thomas
    Vey, Norbert
    Verma, Vivek
    Kobbe, Guido
    Bergua, Juan
    Serrano, Josefina
    Gore, Steven D.
    Zeidan, Amer M.
    BLOOD, 2017, 130
  • [48] The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia
    Fathi, Amir T.
    Chen, Yi-Bin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (04) : 330 - 336
  • [49] Y Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes
    Zeidan, Amer M.
    Gilligan, Adrienne M.
    Gautam, Santosh
    Grinblatt, David L.
    Elsouda, Dina
    Sullivan, Loretta
    Pandya, Bhavik J.
    BLOOD, 2020, 136
  • [50] Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam M.
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Benton, Christopher B.
    Benton, Christopher B.
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa E.
    Jain, Nitin
    Kornblau, Steven M.
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias
    Masarova, Lucia
    Rytting, Michael E.
    Thompson, Philip A.
    Wang, Sa A.
    Konoplev, Sergej
    Chen, Zhining
    Goswami, Maitrayee
    Maduike, Rita
    Guerrero, Julio A.
    Zhang, Qi
    Cavazos, Antonio
    Ma, Helen
    Bivins, Carol A.
    Wade, Allison
    Adewale, Shadiat L.
    Tse, Susan
    Thomas, Robin
    Vaughan, Kenneth
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD, 2019, 134
12345